Microglial cells are main actors in acute neuroinflammation, during which they activate to later
return to a basal resting state. Sometimes they retain immune memory of previous
neuroinflammatory events, turning into primed microglia, which develop exacerbated responses
to new stimuli. Brain can be depleted of microglia by treatment with the CSF1R inhibitor PLX5622.
Treatment termination allows for microglia regeneration, new cells presenting a resting state. Here we aimed to explore if treatment with lower doses of PLX5622 can reverse microglial priming. We induced
microglial priming in mice by provoking acute neuroinflammation by icv
administration of neuraminidase. After 3 weeks, when neuroinflammation is largely solved, mice
were treated with a daily dose of PLX5622 for 12 days. Then, microglial repopulation was allowed
for 7 weeks. Finally, a second stimulus was applied (ip LPS) to induce inflammatory
activation of primed microglia, and animals were sacrificed 12 hours later. Brains were collected
to analyze microglial cell number and activation by morphological analysis, and expression level
of key genes by qPCR; these parameters were evaluated in two regions: the periventricular area of
the hypothalamus and the hippocampus. In hypothalamic paraventricular nucleus the number of
microglial cells was the same regardless the treatment; however, it was slightly reduced in the
dentate gyrus of the hippocampus of PLX5622 treated mice. Morphological analysis of microglial
cells was carried out by fractal, sholl and skeleton analysis. All of them pointed that microglia
sampled from NA injected mice had a more activated profile (less ramified cells), which was
reversed by PLX5622 treatment. Besides, expression of pro-inflammatory related genes (IL1β,
IL6, TNFα, NLRP3, TLR4) pointed to the same direction. Thus, our results suggest that PLX5622
used at low doses reverses microglial priming, while does not fully deplete microglial population.
Buscar en Dimension